20 results
8-K
EX-99.5
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
ValenzaBio and ProBioGen AG (“ProBioGen”). ValenzaBio originally entered into the ProBioGen Agreement to research, develop and commercialize innovative
8-K
EX-99.4
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
into the ProBioGen Agreement to research, develop and commercialize innovative therapies using ProBioGen’s proprietary technology, and ValenzaBio
DEFM14A
ELYM
Eliem Therapeutics Inc
4 Jun 24
Proxy related to merger
8:00am
originally entered into the ProBioGen Agreement in connection with the research, development and commercialization of innovative therapies using … ”). ValenzaBio originally entered into the ProBioGen Agreement to research, develop and commercialize innovative therapies using ProBioGen’s proprietary
PREM14A
ELYM
Eliem Therapeutics Inc
17 May 24
Preliminary proxy related to merger
4:36pm
. ValenzaBio originally entered into the ProBioGen Agreement in connection with the research, development and commercialization of innovative therapies using … into the ProBioGen Agreement to research, develop and commercialize innovative therapies using ProBioGen’s proprietary technology, and ValenzaBio used this technology
10-K
xcysvxc buce1rx
7 Mar 22
Annual report
4:03pm
10-Q
7l1dg1v
13 Sep 21
Quarterly report
4:01pm
424B4
fl5oxs0mc7ilmfv kzs
11 Aug 21
Prospectus supplement with pricing info
5:05pm
S-1/A
3ra oevm9cfxkeuu5
2 Aug 21
IPO registration (amended)
6:08am
S-1
u1ioz7n1i3g8lmn8o
16 Jul 21
IPO registration
5:02pm
DRS/A
144xa7i
12 Jul 21
Draft registration statement (amended)
12:00am
DRS/A
pmxx3jg
21 Jun 21
Draft registration statement (amended)
12:00am
DRS
lon awyffdjr
12 May 21
Draft registration statement
12:00am
- Prev
- 1
- Next